Novo A/S has appointed Kasim Kutay as its new CEO. Kasim started his career at Morgan Stanley, where he spent 18 years advising mainly healthcare companies.
In 2009, he joined Moelis & Company, a leading global independent investment bank. Kasim Kutay is currently Co-head of Europe at Moelis & Company and also serves on the bank’s Management Committee.
Novo A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. Novo A/S is the holding company in the Novo Group and responsible for managing the Foundation’s assets. Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets.
Source: Pharma Times
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.